Vertex's CFTR modulator Alyftrek is growing in the CF market, with regulatory filings under review in Canada, Australia, and New Zealand.
5 reports, 1 independent
Updated Aug 5
Gone quiet
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vertex's CFTR modulator Alyftrek is growing in the CF market, with regulatory filings under review in Canada, Australia, and New Zealand.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Alyftrek sales are growing, and regulatory reviews are underway in multiple countries.
- EC grants approval for Alyftrek for cystic fibrosis treatment.
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- tickerreport.com
- Unknown outlet
- Unknown outlet
- Unknown outlet